Rifadin (Rifampin) Injection shortage
Rifadin (and its generic, rifampin injections) is on the FDA’s drug shortage list as of Oct 8, 2026. Brand-name Rifadin is short too: Sanofi-Aventis U.S. says 1 of its 2 Rifadin products is unavailable and 1 is being discontinued. The companies reporting it blame a company discontinuing its product and rising demand.
Rifadin (rifampin) injection is in a lasting shortage, driven mainly by generic supply problems — the brand's maker, Sanofi-Aventis, is permanently discontinuing it, while generic versions remain mostly unavailable. The 600 mg vial has one limited source, but the 600 mg/10 mL concentration has no listed supply from any reporting manufacturer.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this medicine? See the ‘What to do’ note from Dr. Brian Staiger, PharmD →Is Rifadin still in shortage? — status as of Oct 8, 2026
Yes, still current as of Oct 8, 2026. 1 of the 2 strengths is still made by at least one company; 1 is not. 1 of the 3 companies that reported this shortage says it still has some supply, and we could not find another company that sells it. Your pharmacy may still need to order it.
The charts count only the companies that reported this shortage to the FDA; companies that haven’t reported a problem are in the green card, and the Supply-Risk rating counts them too.
Shortage timeline
-
Oct 6, 2026Currently in shortage4 of 4 products affected.
-
Oct 5, 2026FDA refreshed this shortage record1 product updated.
-
Sep 18, 2026FDA refreshed this shortage record1 product updated.
-
Apr 20, 2026FDA refreshed this shortage record1 product updated.
-
Apr 20, 2026More presentations reported1 more product added to the shortage.
-
Feb 17, 2021First reported to the FDA3 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
Which Rifadin products are affected — by company
Company: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Rifampin Injection, 600 mg | 600 mg | Limited Availability | Check wholesalers for inventory | Other |
Company: Mylan Institutional, a Viatris Company 📞 800-796-9526 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Rifampin Injection, 600 mg | 600 mg | Unavailable | Estimated recovery: Q4 2026 | Demand increase for the drug |
Company: Sanofi-Aventis U.S. LLC 📞 800-633-1610 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Rifadin Injection, 600 mg | 600 mg | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug |
| To Be Discontinued | Rifadin Injection, 600 mg/10 mL | 600 mg/10 mL | — | Discontinuation of the manufacture of the drug | — |
These rows are company reports to the FDA for Rifampin Injection — they do not cover every company that lists this medicine. A company appears here only if it told the FDA it has a supply problem, so other companies may still have stock. That’s the basis for the Where else can I get Rifadin or its generic? options further down this page.
Why is Rifadin in shortage?
Rifampin injection 600 mg is in short supply right now for a few different reasons depending on the manufacturer. Mylan (a Viatris company) says they can't supply their 600 mg vials right now because more people need this medication than they can currently produce — they expect to have it available again sometime in the fourth quarter of 2026. Fresenius Kabi is still making their 600 mg version, but supply is limited, so availability may vary depending on where you look.
Sanofi-Aventis has permanently stopped making their brand-name version, Rifadin injection 600 mg/10 mL — meaning that specific product won't be coming back from that company. Again, this report only covers these three manufacturers specifically, so supply from other makers may be a separate situation entirely.
Based on the company-reported reason(s) and notes on file with the FDA for Rifampin Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as companies report changes.
What should I do if I take Rifadin?
Rifampin Injection is currently on the FDA shortage list, and I want to walk you through what that means for the version you take.
Here is how the strengths break down. The 600 mg strength still has an available source — one manufacturer (Fresenius Kabi) reports limited availability and suggests checking wholesalers for inventory. The 600 mg/10 mL strength currently has no listed source, as the manufacturer that made it reports it is being discontinued. So if you take the 600 mg, supply exists; if you take the 600 mg/10 mL, that specific product may be gone for good.
The reasons on file include increased demand, a discontinuation by one maker, and "other." This shortage has lasted over a year, and one 600 mg supplier estimates recovery around late 2026. Note this affects the generic injection most; the Rifadin brand's 600 mg/10 mL is the discontinued item.
Please do not stop or change your doses on your own. Then consider these steps:
- If you take the 600 mg, ask your pharmacy to order it — they can check wholesalers and other makers.
- If your strength is discontinued or can't be found, ask your prescriber or pharmacist about options.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is national, manufacturer-reported data and may not match your local pharmacy's actual stock.
- Ask your pharmacy to check other companies’ versions, other strengths, package sizes, and nearby stores — the options below are a starting point.
- If this is part of an ongoing or essential regimen (for example HIV, seizure, heart, transplant, diabetes or mental-health medicines), arrange continued supply before you run out rather than rationing doses.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Rifadin or its generic?
FDA shortages are company-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every company that lists rifampin injections is necessarily short. Below are the other listings in the current FDA NDC Directory that are not reported in shortage: the same medicine from companies that haven’t reported a problem (the reporting companies are excluded), and other dosage forms. These are generic versions of Rifadin — a switch from the brand goes through your pharmacist or prescriber. Some listings are repackagers, which relabel another company’s product. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Other dosage forms of rifampin
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 4 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Rifadin IV 600 mg/10mL | Sanofi-Aventis | 1 vial | — | AP | Discontinued |
| Rifampin 600 mg | Hikma | 1 injection | — | AP | FDA listed |
| Rifampin 600 mg | Fresenius | 1 vial | — | AP | FDA listed |
| Rifampin 600 mg/10mL | Mylan | 1 vial | — | AP | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Rifadin — that fall in the same broad treatment class (antitubercular antibiotics) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Codes & classification for pharmacists and billers
Where does this data come from?
Other anti-infective shortages
Rifadin shortage FAQs
Is Rifadin still in shortage?
Which strengths of Rifadin are affected?
Why is Rifadin in shortage?
Which Rifadin products are affected?
When will Rifadin be available again?
Can I still get Rifadin or its generic somewhere?
Is the brand or the generic affected?
What should I do if I take Rifadin?
Still have a question about the Rifadin shortage?
Ask a pharmacist about this shortage →View Rifampin Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (companies listing the same ingredient & form — the "other companies" the rating counts); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.